Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2024

G-CSF Granulocyte Colony Stimulating Factors Global Market Report 2023 – By Type (Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications), By Product (Tablet, Capsule, Other Products) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
G-CSF (Granulocyte Colony Stimulating Factors) Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

G-CSF (granulocyte colony stimulating factors) market refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumors, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.

The main types of G-CSF (granulocyte colony stimulating factors) market are lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco), and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablets, capsules, and others and are used in oncological diseases, blood disorders, growth hormone deficiencies, and chronic and autoimmune disorders, among others.

The global G-CSF (granulocyte colony stimulating factors) market is segmented -

1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)

2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications

3) By Product: Tablet, Capsule, Other Products

The global G-CSF (granulocyte colony stimulating factors) market grew from $7.99 billion in 2022 to $8.43 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of G-CSF (granulocyte colony stimulating factors) is expected to grow from $9.94 billion in 2027 at a CAGR of 4.2%.

The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in December 2020, according to the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency that publishes research and data on cancer, it is anticipated that 28.4 million new cases of cancer will be diagnosed worldwide in 2040, up 47% over the anticipated 19.3 million cases in 2020, primarily due to population growth and aging. G-CSF (granulocyte colony stimulating factor) is a class of growth factors that produce white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF (granulocyte colony stimulating factor) market.

Major players in the G-CSF (granulocyte colony stimulating factors) market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, StadaArzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories, and Celltrion Inc.

The high cost is a key factor limiting the growth of the G-CSF (granulocyte colony stimulating factor) market. Improved chemotherapy administration is responsible for the rise in immediate medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the cost of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (granulocyte colony stimulating factor) market.

Companies in the G-CSF (granulocyte colony stimulating factor) market are focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For example, in 2022, Evive Biotech, a Singapore based biopharmaceutical company collaborated with Germany based pharmaceutical company, APOGEPHA to enter into an exclusive long-term license agreement for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a novel dimeric G-CSF long-acting fusion protein without pegylation.  

In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, G-CSF drugs would be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of biosimilars for the treatment of eye related diseases.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2022. The regions covered in the G-CSF (granulocyte colony stimulating factor) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the G-CSF (granulocyte colony stimulating factor) industry report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. G-CSF (Granulocyte Colony Stimutating Factors) Market Characteristics

    3. G-CSF (Granulocyte Colony Stimutating Factors) Market Trends And Strategies

    4. G-CSF (Granulocyte Colony Stimutating Factors) Market – Macro Economic Scenario

    4.1 COVID-19 Impact On G-CSF (Granulocyte Colony Stimutating Factors) Market

    4.2 Ukraine-Russia War Impact On G-CSF (Granulocyte Colony Stimutating Factors) Market

    4.3 Impact Of High Inflation On G-CSF (Granulocyte Colony Stimutating Factors) Market

    5. G-CSF (Granulocyte Colony Stimutating Factors) Market Size And Growth

    5.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. G-CSF (Granulocyte Colony Stimutating Factors) Market Segmentation

    6.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Lenograstim (Granocyte)

    Filgrastim (Neupogen, Zarzio, Nivestim, Accofil)

    Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)

    Lipegfilgrastim (Lonquex)

    6.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oncological Diseases

    Blood Disorders

    Growth Hormone Deficiencies

    Chronic and Autoimmune Disorders

    Others

    6.3. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Tablet

    Capsule

    Others

    7. G-CSF (Granulocyte Colony Stimutating Factors) Market Regional And Country Analysis

    7.1. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market

    8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China G-CSF (Granulocyte Colony Stimutating Factors) Market

    9.1. China G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    9.2. China G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India G-CSF (Granulocyte Colony Stimutating Factors) Market

    10.1. India G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market

    11.1. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market

    12.1. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market

    13.1. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market

    14.1. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market

    15.1. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    15.2. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK G-CSF (Granulocyte Colony Stimutating Factors) Market

    16.1. UK G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market

    17.1. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France G-CSF (Granulocyte Colony Stimutating Factors) Market

    18.4. France G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market

    19.1. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    19.2. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market

    20.1. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America G-CSF (Granulocyte Colony Stimutating Factors) Market

    21.1. North America G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    21.2. North America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA G-CSF (Granulocyte Colony Stimutating Factors) Market

    22.1. USA G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    22.2. USA G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America G-CSF (Granulocyte Colony Stimutating Factors) Market

    23.1. South America G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    23.2. South America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market

    24.1. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market

    25.1. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    25.2. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market

    26.1. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market Overview

    26.2. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. G-CSF (Granulocyte Colony Stimutating Factors) Market Competitive Landscape And Company Profiles

    27.1. G-CSF (Granulocyte Colony Stimutating Factors) Market Competitive Landscape

    27.2. G-CSF (Granulocyte Colony Stimutating Factors) Market Company Profiles

    27.2.1. BioCad

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Teva Pharmaceuticals

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Pfizer

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Intas Pharmaceuticals

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Novartis AG

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. G-CSF (Granulocyte Colony Stimutating Factors) Pipeline Analysis

    29. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimutating Factors) Market

    30. G-CSF (Granulocyte Colony Stimutating Factors) Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: BioCad Financial Performance
  • Table 47: Teva Pharmaceuticals Financial Performance
  • Table 48: Pfizer Financial Performance
  • Table 49: Intas Pharmaceuticals Financial Performance
  • Table 50: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: BioCad Financial Performance
  • Figure 47: Teva Pharmaceuticals Financial Performance
  • Figure 48: Pfizer Financial Performance
  • Figure 49: Intas Pharmaceuticals Financial Performance
  • Figure 50: Novartis AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report